Financial Disclosures

doi:10.1378/chest.126.3_suppl.167S

HOME

HELP

FEEDBACK

SUBSCRIPTIONS

Financial Disclosures

Dr. Guyatt has received research support from Abbott LaboratoriesLimited, AstraZeneca AB, Eli Lilly Canada, Leo Pharma, and Aventis.

Dr. Albers has received research support and honoraria as aconsultant from AstraZeneca, Bristol- Myers Squibb, BoehringerIngelheim, Genentech and Sanofi-Arganon.

Dr. Schünemann has received research funding from AstraZeneca,Boehringer Ingelheim, Pfizer, and Amgen Inc. He has receivedhonoraria and consultant fees from AstraZeneca, Boehringer Ingelheim,and Amgen that were deposited into research accounts at theUniversity of Buffalo and McMaster University.

Ms. Munger has received no research support.

Dr. O’Donnell has no conflicts to disclose.

Dr. Brower has not received any research funding and has nodisclosures.

Dr. Crowther has received research funding, speakers fees and/orfees for sitting on advisory boards from Aventis Pharma, Pfizer(formally Pharmacia), Leo Laboratories, and Sanofi-Organon.

Dr. Cook has received research support from Eli Lilly Canada,Pharmacia (now Pfizer) Leo Pharma, and Aventis. She has receivedhonoraria for consulting which was deposited into a McMasterResearch Account from Eli Lilly Canada and Pharmacia (now Pfizer).

Dr. Guyatt has received research support from Abbott LaboratoriesLimited, AstraZeneca AB, Eli Lilly Canada, Leo Pharma, and Aventis.

Dr. Jaeschke has received honoraria as a speaker at educationalevents from AstraZeneca, Bristol-Myers Squibb, MSD, and EliLilly.

Dr. Stephen Pauker has received research funding from Schering-Plough,but none related to anti-thrombotic therapy. Dr. Pauker is amember of the Board of Regents of the American College of Physicians.

Dr. Raschke has received honoraria for his participation onadvisory boards and/or as a speaker at educational events fromBerlex, Lederle, and Aventis.

Dr. Hirsh has received research funding from AstraZeneca andhas received honararia for his participation on advisory boardsand/or as a speaker at educational events from AstraZeneca.

Dr. Poller is employed in an honorary capacity as Professorin the University of Manchester. He receives research fundingonly from the European Community and Manchester Thrombosis ResearchFoundation, a registered charity. No honoraria have been receivedfrom industry for the past 3 years.

Dr. Bussey has received research funding from Aventis, Organon-Sanofi-Synthelabo,AstraZeneca, Bristol-Myers Squibb, Bertek Pharmaceuticals, andNovartis and has participated on advisory boards and/or researchsteering committees for Aventis, Organon-Sanofi-Synthelabo,and AstraZeneca. He also has received speaking honoraria fromand/or served as a consultant for Aventis, AstraZeneca, Bristol-MyersSquibb, and Organon-Sanofi-Synthelabo.

Dr. Jacobson has received research funding from AstraZeneca,Bristol-Myers Squibb, Aventis, Sanofi, Organon, Roche Diagnostics,Hemosense, International Technidyne, and Lifescan, and has receivedhonoraria for his participation on advisory boards and/or asa speaker at educational events from AstraZeneca, Aventis, Bristol-MyersSquibb, and Lifescan.

Dr. Hylek has received research funding from Pfizer and Bristol-MyersSquibb and has received honoraria for participation as a speakerat an educational event from Bristol-Myers Squibb.

Dr. Coller is an inventor of abciximab and an inventor of technologiesunderlying the original rapid platelet function assay (RPFA)and its subsequent variants. As a result, he has an interestin royalties paid for the sales of abciximab and the RPFA. Heis also a member of the scientific advisory board of Accumetrics,San Diego, CA, the manufacturer of the RPFA. Supported in partby grants 19278 and 54469 from the National Heart, Lung, andBlood Institute. Dr. Coller did not participate in developingany specific recommendations concerning the use of GPIIb/Iiaantagonists or the value of monitoring antiplatelet therapy.

Dr. FitzGerald is the Robinette Foundation Professor of CardiovascularMedicine. His work is supported by grants HL62250, HL61364,HL54500, and RR00040.

Dr. Hirsh has received research funding from AstraZeneca andhas received honararia for his participation on advisory boardsand/or as a speaker at educational events from AstraZeneca,Aventis Pharma, Sanofi-Synthelabo-Organon, Bristol-Myers Squibb,GlaxoSmithKline and Asahi.

Dr. Gerald Roth has no conflicts to declare.

Dr. Hirsh has received research funding from AstraZeneca andhas received honoraria for his participation on advisory boardsand/or as a speaker at educational events from AstraZeneca,Aventis Pharma, Sanofi-Synthelabo-Organon, Bristol-Myers Squibb,GlaxoSmithKline and Asahi.

Dr. Raskob has received research funding from Sanofi-Synthelabo,Organon, Aventis, and Bristol-Myers Squibb, and has receivedhonoraria for his participation on advisory boards and/or asa speaker at educational events for Sanofi-Synthelabo, Organon,AstraZeneca, Pharmacia, Aventis, Amgen, and Pharmion.

Dr. Beyth has no conflicts of interest to disclose.

Dr. Kearon has received research funding from AstraZeneca andhas received honoraria for his participation on advisory boardsand/or as a speaker at educational events from AstraZeneca,Sanofi-Synthelabo-Organon, and Asahi.

Dr. Greinacher has received research funding from celltech,Berlex, Pharmion, Novartis, and has received honoraria for hisparticipation on advisory boards and/or as a speaker at educationalevents from Berlex, Pharmion, Celltech, Mitsubishi, AventisPharma, SheringAG.

Dr. Pineo has received research funding from Aventis, EmisphereTechnologies, Leo Pharma, and Pharmacia and has participatedon advisory boards and/or research steering committees for AstraZeneca,Aventis, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer-Pharmacia,and Sanofi-Synthelabo-Organon;

Dr. Heit has received research funding from AstraZeneca, Aventis,and Corvas and has participated on advisory boards and/or researchsteering committees for AstraZeneca, Aventis, and Pharmacia;

Dr. Bergqvist has participated on advisory boards and/or researchsteering committees for AstraZeneca, Aventis, Boehringer Ingelheim,Pharmacia/Pfizer, and Sanofi-Synthelabo;

Dr. Lassen has received research funding from Sanofi-Synthelaboand has participated on advisory boards and/or research steeringcommittees for AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-MyersSquibb, GlaxoSmithKline, Leo Pharma, Mitsubishi Pharma, VivolutionInc, Wyeth, and Yamanautchi;

Dr. Colwell has received research funding from Amgen, AstraZeneca,Baxter, and Sanofi-Synthelabo and has participated on advisoryboards and/or research steering committees for AstraZeneca,Aventis, Pharmacia, and Sanofi-Synthelabo; and Dr. Ray has nopotential conflicts.

Dr. Agnelli has received honoraria for his participation onadvisory boards and/or as speaker at educational events fromAstraZeneca, Aventis Pharma and Sanofi-Synthelabo-Organon.

Dr. Hull has received research funding from Aventis, Pharmacia(now Pfizer), Leo Pharma, Emisphere Technologies, Dupont Pharmaceuticals(now Bristol-Myers Squibb) and Pharmion. He has received honorariafor his participation on advisory boards and/or as a speakerat educational events from Aventis, Bayer, Pharmacia (now Pfizer),Leo Pharma, Emisphere Technologies, Dupont Pharmaceuticals (nowBristol-Myers Squibb) and Pharmion.

Dr. Thomas Hyers has received honoraria as a speaker for AstraZeneca,Aventis, Boehringer Ingelheim, GlaxoSmithKline, Organon-Sanofi,and Pharmacia. He has served as a consultant for AstraZenecaand Aventis.

Dr. Albers has received research support and honoraria as aconsultant from AstraZeneca, Bristol- Myers Squibb, BoehringerIngelheim, Genentech and Sanofi-Arganon.

Dr. Dalen is a consultant for DuPont Pharma, now Bristol-MyersSquibb, AstraZeneca, and Sanofi-Organon.

Dr. Go has nothing to declare.

Dr. Halperin has received research support from AstraZenecaand is a consultant for AstraZeneca. He is on the speakers bureaufor Bristol-Myers Squibb and Sanofi.

Dr. Manning is a consultant for AstraZeneca, Bristol-Myers Squibb,and Phillips Medical Systems.

Dr. Stein received honoraria for speaking at educational eventsfrom Aventis Pharma and Dupont Pharma. He was a consultant forShiley several years ago.

Dr. Al-Ahmad has nothing to declare.

Dr. Stephen Pauker has received research funding from Schering-Plough,but none related to anti-thrombotic therapy. Dr. Pauker is amember of the Board of Regents of the American College of Physicians.

Antithrombotic and Thrombolytic Therapy for Ischemic Stroke

Dr. Albers has received research support and honoraria as aconsultant from AstraZeneca, Bristol- Myers Squibb, BoehringerIngelheim, Genentech and Sanofi-Arganon.

Dr. Easton has received honoraria for his participation on advisoryboards or as a speaker at educational events from BoehringerIngelheim, Bristol- Myers Squibb, and Sanofi-Synthelabo.

Dr. Sacco has received research funding from GlaxoSmithKlineand Pfizer, and has received honoraria for his participationas a consultant on advisory boards, data and safety monitoringboards and/or as a speaker at educational events from BoehringerIngelheim, sanofi-Synthelabo, Bristol-Myers Squibb, Pfizer,AstraZeneca, GlaxoSmithKline, and Texas Biotechnology.

Dr. Teal has received honoraria for participation on advisoryboards and/or as a speaker at medical education events supportedby Boehringer-Ingelheim, Sanofi-Synthelabo and Bayer, Servier,Aventis, PAION, AstraZeneca, and Hoffman-LaRoche. He has servedon research steering committees for clinical trials conductedby Boehinger-Ingelheim, Bayer, ONO Pharnaceuticals and Pfizerand Eli-Lilly, EKOS, GlaxoSmithKline, and Yamaguichi.

Dr. Ezekowitz has received research funding from AstraZeneca/B.I.and is a consultant for AstraZeneca, B.I. Eli Lilly, Pfizer,Aventis, Glaxo, and Wyeth.

Dr. Meade has received payment as a member of ISEAC, the IndependentScientific and Ethics Advisory Committee to IMS Healthcare,a general practice database used for research and has receivedhonoraria from Bayer.

Dr. Vorchheimer has received research funding from AstraZeneca,Sanofi, and has received honoraria for his participation onadvisory boards and/or as a speaker at educational events sponsoredby Millennium Pharmaceuticals, and Sanofi.

Dr. Guyatt has received research support from Abbott LaboratoriesLimited, AstraZeneca AB, Eli Lilly Canada, Leo Pharma, and Aventis.

Dr. Cannon, through the Department of Medicine of brigham andWomen’s Hospital, currently receives research grant supportfrom Bristol-Myers Squibb, Merck, and Sanofi-Synthelabo. Heis a consultant to Asahi Chemical Company, Bayer, Pfizer Limited,Vertex, Medicines Company, Ortho-Clinical Diagnostics, AstraZeneca,GlaxoSmithKline. Dr. Cannon is on the speaker bureau of Aventis,Bristol-Myers Squibb, Centocor, Eli Lilly, Genentech, Merck,Millennium, Sanofi-Synthelabo. He has received honoraria forpreparation of educational materials from Best Med, DiscoveryEast, Excerpta Medica, Medical Decision Point, and NCME.

Dr. Robert Harrington has received research grants through theDuke Clinical Research Institute from Aventis, AstraZeneca,Millennium, Schering, Merck, Lilly, Centocor, Roche, The MedicinesCompany, BMS, Sanofi, Glaxo, Daiichi.

Dr. Goodman has received research funding and has received honorariafor his participation on advisory boards and/or as a speakerat educational events from AstraZeneca, Aventis Pharma, Bayer,Biovail, Boehringer Ingelheim, BrystolMyers Squibb, CanAm, Centocor,Daiichi, Eli Lilly, Fournier Pharma, Hoffman-La Roche, Key Schering/ScheringPlough, Millenium, Merck, Novartis, Sanofi Synthelabo, Servier,and Solvay.

Dr. Wilcox has received research funding from AstraZeneca, Aventisand Bristol-Myers Squibb.

Dr. Ohman has received research grants from the following organizations:BMS, Sanofi, Millennium, Schering-Plough, Aventis, and Berlex.

Dr. Berger has received a small amount of research support fromBristol-Myer Squibb/Sanofi and Cordis/Johnson & Johnson.He formerly served on a scientific advisory board for Bristol-MyerSquibb/Sanofi. He currently serves on a scientific advisoryboard for Cordis/Johnson & Johnson and Genentech. He hasspoken at scientific symposia supported by Merck, Aventis, Bristol-MyerSquibb/Sanofi and the Medicines Co.

Dr. Ohman has received research grants from the following organizations:BMS, Sanofi, Millennium, Schering-Plough, Aventis, and Berlex.

Dr. Weitz has received research funding from AstraZeneca andThe Medicines Company and has received honoraria for his participationon advisory boards and/or as a speaker at educational eventsfrom AstraZeneca, Aventis, and Daiichi.

Dr. Dalen has received honoraria as a consultant for DuPontPharma (now Bristol-Myers Squibb), AstraZeneca and Sanofi-Organon.

Dr. Gutterman owns stock in Johnson & Johnson.

Dr. Jackson has not received industry funding for research andhas not received honoraria during this time period.

Dr. Lip has received research funding from AstraZeneca, Merck,and Servier, and has received honoraria for his participationon advisory boards and/or as a speaker at educational eventsfrom AstraZeneca, Servier, Boehringer Ingelheim, Novartis, Mitsubishi,Pharma, Yamanuchi, Bristol-Myers Squibb, Sanofi-Synthelabo-Organon,GlaxoSmithKline, Sankyo and Merck.

Dr. Tangelder is at present an employee of Sanofi-Synthelabo.During the preparation of the text for this guideline, he hadnothing to declare.

Dr. Verhaeghe has received research support from AstraZenecaAB and Sanofi-Organon.

Dr. Greer has received honoraria for his participation on advisoryboards and/or as a speaker at educational events from Aventis.

Dr. Massicotte has received research funding from Leo Pharmaand Pfizer and AstraZeneca and has received honoraria for herparticipation on the advisory boards and/or as a speaker ateducational events from AstraZeneca, Aventis Pharma, Lifescan,Leo Pharma, Sanofi-Synthelabo-Organon, and Bristol-Myers Squibb.

Dr. Michelson has received research funding from Centocor, Lilly,Bristol-Myers Squibb and Sanofi-Synthelabo.

Dr. Grimshaw has received funding from Astra Zeneca administeredthrough the Canadian Cardiovascular Society to develop a studyprotocol.

Dr. Heffner has not received research funding from any companyrelated to issues of thrombosis or thrombolytic therapy.

Dr. Tapson has received research funding from Aventis, and AstraZeneca,and has received honoraria for his participation on advisoryboards and as a speaker at educational events from Aventis,AstraZeneca, and Berlex.

Dr. Guyatt has received research support from Abbott LaboratoriesLimited, AstraZeneca AB, Eli Lilly Canada, Leo Pharma, and Aventis.

This Article

Full Text (PDF) Free

Supplement Sponsorship

Submit a response

Alert me when this article is cited

Alert me when eLetters are posted

Alert me if a correction is posted

Services

Email this article to a friend

Similar articles in this journal

Alert me to new issues of the journal

Add to My Personal Article Archive

Download to citation manager

Citing Articles

Citing Articles via Google Scholar

Google Scholar

Search for Related Content